Eli Lilly and Company (NYSE:LLY) Shares Down 1.2% – Time to Sell?

Shares of Eli Lilly and Company (NYSE:LLY) traded down 1.2% on Monday . The company traded as low as $1,147.00 and last traded at $1,160.57. 2,818,274 shares traded hands during trading, a decline of 9% from the average daily volume of 3,082,697 shares. The stock had previously closed at $1,174.61.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Merida acquisition expands immunology pipeline: Lilly agreed to acquire privately held Merida Biosciences for up to approximately $2.88 billion in cash. Merida’s antibody-engineering platform is designed to remove disease-causing antibodies while preserving normal immune function. Its lead program, MER511, has produced initial Phase 1 data showing reductions in thyroid-stimulating antibodies, potentially supporting treatments for Graves’ disease, thyroid eye disease, food allergies and other autoimmune conditions. Eli Lilly to buy Merida Biosciences in $2.88 billion deal
• Positive Sentiment: Mounjaro receives expanded FDA approval: The FDA approved Mounjaro to reduce cardiovascular risk in high-risk patients with type 2 diabetes, expanding the drug’s addressable market and potentially strengthening Lilly’s diabetes franchise. LLY’s Mounjaro Gets FDA Nod to Cut Cardiovascular Risk in Diabetes
• Positive Sentiment: Encouraging Taltz-Zepbound data: One-year Phase 3b results showed that combining Taltz with Zepbound sustained or improved psoriasis and psoriatic arthritis outcomes, while also improving or maintaining metabolic measures in adults with obesity or overweight. The findings could support broader use of Lilly’s medicines in immunometabolic care. New Phase 3b data on Lilly’s Taltz and Zepbound
• Neutral Sentiment: Deal execution will be key: The Merida transaction diversifies Lilly beyond its blockbuster obesity and diabetes products, but MER511 remains an early-stage asset and the acquisition requires a sizable cash commitment before commercial benefits are established.
• Negative Sentiment: Increasing GLP-1 competition: Investors are monitoring potential threats from Amylyx and Novo Nordisk as rival companies advance competing GLP-1 treatments, including more convenient oral options. Lilly’s dependence on Mounjaro and Zepbound makes sustained market leadership important to its valuation. Should Eli Lilly Investors Be Worried About a Threat From Amylyx?

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. The Goldman Sachs Group reissued a “buy” rating and issued a $1,283.00 target price on shares of Eli Lilly and Company in a report on Friday, May 22nd. Citigroup increased their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Cantor Fitzgerald lifted their target price on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Morgan Stanley reaffirmed an “overweight” rating and issued a $1,419.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 6th. Finally, Barclays increased their price target on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research note on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,292.18.

Eli Lilly and Company Stock Performance

The firm’s 50-day moving average price is $1,189.22 and its 200-day moving average price is $1,065.44. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The stock has a market cap of $1.09 trillion, a P/E ratio of 38.95, a PEG ratio of 1.39 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts expect that Eli Lilly and Company will post 36.35 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is currently 23.22%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. The trade was a 56.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares of the company’s stock, valued at $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock worth $15,958,170 in the last quarter. 0.14% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Integrity Financial Corp WA boosted its position in shares of Eli Lilly and Company by 1.3% during the 2nd quarter. Integrity Financial Corp WA now owns 639 shares of the company’s stock worth $767,000 after acquiring an additional 8 shares in the last quarter. Willner & Heller LLC increased its holdings in Eli Lilly and Company by 1.0% in the 2nd quarter. Willner & Heller LLC now owns 917 shares of the company’s stock worth $1,100,000 after purchasing an additional 9 shares in the last quarter. Aspiring Ventures LLC raised its holdings in Eli Lilly and Company by 3.7% in the 2nd quarter. Aspiring Ventures LLC now owns 255 shares of the company’s stock valued at $306,000 after buying an additional 9 shares during the last quarter. Wealthspan Partners LLC raised its stake in shares of Eli Lilly and Company by 0.4% during the second quarter. Wealthspan Partners LLC now owns 2,120 shares of the company’s stock valued at $2,543,000 after acquiring an additional 9 shares during the last quarter. Finally, Navigoe LLC lifted its holdings in Eli Lilly and Company by 8.7% during the 2nd quarter. Navigoe LLC now owns 113 shares of the company’s stock worth $135,000 after buying an additional 9 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.